Study of SCTB14 for untreated advanced non-small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug, SCTB14, as a first treatment for advanced non-small cell lung cancer that has a high level of PD-L1. It aims to see if the drug is safe and effective for people who haven't had other treatments for their cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have stage IIIB, IIIC, or IV non-small cell lung cancer that can't be removed with surgery or cured with chemo and radiation.
- Your tumor must have a PD-L1 score of at least 10% (a test that looks for a protein on your cancer cells).
- You should not have had any prior chemotherapy, immunotherapy, or targeted therapy for this lung cancer.
- You need to be in generally good health (able to care for yourself and up and about at least half the day).
- You cannot have certain gene mutations in your tumor (such as EGFR, ALK, ROS1, or others).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, BL-M14D1, for people with advanced small cell lung cancer, neuroendocrine tumors, or other solid tumors that have no standard treatment. The goal is to see if the drug is safe and possibly effective.
This trial tests a new drug called SCTB14 for people with advanced solid tumors. The goal is to see if it is safe and whether it helps shrink or slow the cancer.
This trial tests a new drug (SCTB41) combined with chemotherapy for people with advanced squamous non-small cell lung cancer who have not had any prior treatment. It aims to see if this combination works better than standard therapy.
This study tests a new combination treatment (SCTB41 plus docetaxel) for people with advanced non-small cell lung cancer who have already tried other treatments. The goal is to see if this combination can help shrink or control the cancer.
This trial tests a new drug called SCTB41 in people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and if it shrinks tumors.
This trial tests an experimental immunotherapy called BNT116, given alone or with other drugs, for people with advanced non-small cell lung cancer (NSCLC). The goal is to see if it is safe and if it can help shrink tumors.
Hear when a new Non-Small Cell Lung Carcinoma (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.